MedTrace Logo

Flo Digital Contraceptive Study

NCT07630064 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3800

Last updated 2026-06-05

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the Flo Digital Contraceptive (FDC) app can effectively prevent unintended pregnancy in women aged 18 years and older residing in the United States. The main questions it aims to answer are:

What is the rate of unintended pregnancy in women aged 18-35 years using FDC as their sole method of contraception under typical-use conditions, measured using the Pearl Index? What is the cumulative probability of unintended pregnancy over 13 menstrual cycles for all participants, including those with regular and irregular cycles?

Participants will:

Use the Flo Digital Contraceptive app in 'prevent pregnancy' mode as their primary method of contraception for up to 13 menstrual cycles or 18 months, whichever comes first Wear an Apple Watch (Series 8 or later, or Ultra) while sleeping to collect nightly wrist temperature data, which the app uses to detect ovulation Log menstrual cycles, sexual activity, and any use of emergency contraception directly in the Flo app Complete monthly electronic surveys (ePROs) administered by the study team covering pregnancy status, adherence, safety, and experience Complete a baseline demographic survey at enrollment and an exit survey at the end of participation

Conditions

  • Contraception Use

Interventions

DEVICE

Flo Digital Contraceptive

The Flo Digital Contraceptive (FDC) is a fertility awareness-based Software as a Medical Device (SaMD) integrated within the Flo Period \& Cycles Tracker app (iOS) in 'prevent pregnancy' mode. The FDC uses a proprietary machine-learning algorithm to classify each day of the user's menstrual cycle as either 'Not fertile' (unprotected intercourse permitted) or 'Use protection' (abstinence or barrier contraception required). Classifications are generated dynamically using menstrual cycle history and overnight wrist-skin temperature measured via Apple Watch (Series 8 or later, or Ultra), synchronized daily through Apple Health, with optional urinary LH test results as a supplementary input. Participants use FDC as their sole method of contraception for up to 13 menstrual cycles or 18 months from device activation, whichever occurs first.

Sponsors & Collaborators

  • Lindus Health

    collaborator INDUSTRY

  • Flo Health Inc.

    lead INDUSTRY

Principal Investigators

  • Shannon Maclaughlan-David, MD, MS · Lindus Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-22
Primary Completion
2028-01-10
Completion
2028-01-10
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07630064 on ClinicalTrials.gov